# Tag.bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tag-bio

- Industry: Software
- Headquarters: San Francisco, US
- Website: www.tag.bio
- Total disclosed funding: $0.1M
- Latest round: Seed (Mar 26, 2019)
- Investors on record: 2

## About

Based in the US, Tag.bio, Inc. provides a data analytics platform tailored for healthcare and life sciences, streamlining data management and fostering collaboration among researchers and data scientists.Tag.bio, Inc. was founded in 2013 and is headquartered in San Francisco, US. The company specializes in data analytics solutions for healthcare and life sciences. Jesse Paquette is the founder, while Tom Covington serves as the CEO. In March 2019, Tag.bio raised USD 0.05 million in Seed funding from DreamIt Ventures, marking its third deal. This funding was pivotal for supporting their growth and product development.Tag.bio primarily offers a data analytics platform designed for healthcare and life sciences, focusing on streamlining data management and facilitating collaboration. The platform employs a data mesh architecture, enabling users to create governed, versioned, and containerized data products from various data sources. Utilizing built-in enterprise CI/CD processes, Tag.bio supports the deployment of these data products within secure computing environments such as AWS, Azure, and GCP. The end users of Tag.bio's services include researchers, physicians, data scientists, and analytics teams across diverse sectors, particularly within the biomedical and pharmaceutical domains. The platform has been instrumental in addressing specific challenges such as secure collaboration, reproducible data science, and the integration of multi-modal data types, thereby catering to a global market, including North America, Europe, and select regions in Asia.Tag.bio operates under a revenue model structured around subscriptions and partnerships with clients in the healthcare and pharmaceutical sectors. The transactions typically involve the deployment of their data products, which are tailored to meet the needs of various stakeholders, including domain experts and data engineers. Clients engage with Tag.bio's offerings to enhance their data analysis capabilities and accelerate AI development through the use of advanced data products and algorithms. While specific pricing details for individual services have not been disclosed, the firm's flagship offerings include tools for building and deploying AI models, which are pivotal for organizations aiming to leverage generative AI in their research and operations. The collaboration with significant healthcare entities further supports the revenue model, providing a steady client base that seeks innovative solutions for data integration and analysis.Following the Seed funding round in March 2019, Tag.bio aims to enhance its data analytics platform with new features tailored to the healthcare sector. The company plans to expand into additional markets in Europe and Asia by the end of 2023, focusing on collaborations with local healthcare providers. The recent funding will be utilized to support the development of these new product features and to facilitate entry into these new geographic regions.

## Funding rounds

- Seed, Mar 26, 2019, $0.1M — DreamIt Ventures
- Seed, Jun 1, 2018 — Newfund

## Investors

- Newfund (https://capitalatlas.ai/funds/newfund) — Seed
- DreamIt Ventures (https://capitalatlas.ai/funds/dreamit-ventures) — Seed